UBE2V1 and hepatocellular carcinoma: In aggregate, UBE2V1 promotes the ubiquitin-mediated proteasomal degradation of VHL, thereby relieving the inhibitory effects of VHL on downstream oncogenic signaling pathways and ultimately facilitating the malignant progression of HCC cells.